Extremalby
Menu
  • Business
    • Entrepreneurship
    • Personal Finance
  • Entertainment
    • Books
    • Celebrity
    • Music
    • TV
  • Sports
    • Golf
    • NCAAB
    • SOCCER
  • Technology
    • Artificial intelligence
    • Internet
    • Mobile
  • Contact Us
  • About Us
  • Important Links
    • Cookie Policy US
    • DMCA
    • Terms and Conditions
    • Privacy Policy
Menu
FDA approves new kind of diabetes drug with anti-obesity potential

FDA approves new kind of diabetes drug with anti-obesity potential

Posted on May 16, 2022 by mangakiko

The US Food and Drug Administration (FDA) has approved a new kind of treatment for type 2 diabetes. The once-weekly injection, called Mounjaro (tirzepatide), was found to be more effective at controlling blood sugar levels than other current treatments, and a recent trial found the drug may also be useful as an anti-obesity therapy.

“Given the challenges many patients experience in achieving their target blood sugar goals, today’s approval of Mounjaro is an important advance in the treatment of type 2 diabetes,” said Patrick Archdeacon, from the FDA’s Center for Drug Evaluation and Research.

Mounjaro falls in a new class of drug treatments for diabetes developed to mimic a hormone called glucagon-like peptide-1 (GLP-1), which is naturally released by the intestines and known to regulate blood sugar and appetite. The first drug targeting this GLP-1 mechanism, called Wegovy, was approved for type 2 diabetes back in 2017.

This new drug works slightly differently to Wegovy. It has been designed to mimic GLP-1 and another gut hormone called gastric inhibitory polypeptide (GIP). Clinical trials have found the dual action GLP-1 and GIP agonist can be more effective as a type 2 diabetes treatment than therapies solely targeting GLP-1.

The FDA’s approval of Mounjaro is specifically limited to adults with type 2 diabetes. It is also recommended the drug be used to control blood sugar alongside a diet and exercise program.

Interestingly, these GLP-1 therapies have been recently investigated as strong anti-obesity medicines. Although Wegovy was initially approved by the FDA as a diabetes treatment, subsequent clinical trials found it was an effective anti-obesity drug in overweight non-diabetic subjects. Last year the FDA authorized Wegovy as an anti-obesity treatment.

Just last month preliminary data was reported from a large Phase 3 trial testing the anti-obesity properties of Mounjaro. These results, yet to be published in a peer-reviewed journal, indicated around two-thirds of overweight subjects on a high dose of Mounjaro dropped 20 percent of their total body weight after using the drug for a year.

The anti-obesity properties of Mounjaro are still being explored across several ongoing clinical trials and this authorization by the FDA does not approve Mounjaro for any uses beyond type 2 diabetes.

Sources: FDA, Ely Lilly

Share this:

  • Twitter
  • Facebook
  • More
  • Reddit
  • Pinterest
  • Telegram
  • WhatsApp

Related

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent Posts

  • Best Forex Trading Market Internationally
  • All Essential Tips About Forex Trading
  • How to Invest In Forex Trading in 2023
  • The importance of modern forex levels today 2022
  • What about forex trading and how to deal with it step by step?

Recent Comments

No comments to show.

Archives

  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • June 2022
  • May 2022

Categories

  • Artificial intelligence
  • Books
  • Business
  • Celebrity
  • Entertainment
  • Entrepreneurship
  • Environment
  • forex
  • Golf
  • Internet
  • Mobile
  • Music
  • NCAAB
  • Personal Finance
  • Physics
  • SOCCER
  • Sports
  • Technology
  • TV
©2023 Extremalby | WordPress Theme by Superbthemes.com